{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '9.5.5.1.9 Reporting of IND Safety Reports', 'The Sponsor will notify the US FDA and all Investigators on any new serious risks associated', 'with the drug.', '9.5.5.1.10 Reporting of Suspected Unexpected Serious Adverse Reactions in the EU', 'The Sponsor or designee will report all Suspected Unexpected Serious Adverse Reactions', '(SUSARs), to the competent authorities and the concerned ethics committee according to', 'applicable law. Investigators will also be informed according to local requirements.', '9.5.5.1.11 Development Safety Update Reports', 'The Sponsor will prepare and submit annual safety reports to competent authorities and', 'concerned ethics committees.', '9.5.5.2 Pregnancy Reporting', 'Pregnancy testing will be performed for women of childbearing potential (including those with', 'an onset of menopause <2 years prior to Screening, non-therapy-induced amenorrhea for', '<12 months prior to Screening, or not surgically sterile [absence of ovaries and/or uterus]) at', 'Screening, Baseline, prior to dosing during the Treatment Period (Weeks, 3, 6, 9, 12, 15, and 21),', 'the end of the Treatment Period (Week 24 or PW), and at Weeks 28, 36, and 48 during the', 'Follow-Up Period; if a subject discontinues study participation during the Follow-Up Period', 'prior to the Week 48 Visit, a pregnancy test will be performed at the PW assessment. A serum', 'pregnancy test will be performed at Screening and urine pregnancy tests will be performed prior', 'to dose at all other visits, as applicable; the serum sample will be analyzed at a central study', 'laboratory and the urinary pregnancy tests will be performed locally.', 'If a female subject becomes pregnant during the Treatment Period, she should immediately', 'notify the Investigator, and teprotumumab dosing should be permanently discontinued.', 'Pregnancy occurring in the partner of a male subject participating in the study should be reported', 'to the Investigator and the Sponsor. Monitoring of the partner should continue until conclusion', 'of the pregnancy.', 'Pregnancies occurring up to 180 days after the last dose must also be reported to the Investigator.', 'The Investigator should report pregnancies to the Sponsor within 24 hours by submitting the', 'completed pregnancy report form by email to', 'fax, or', \"telephone within 24 hours after becoming aware that the subject/subject's female partner has\", 'become pregnant (see Appendix 17.1 for contact information). The Investigator should counsel', 'the subject and discuss the possible risks of continuing the pregnancy. If pregnancy continues,', 'monitoring should also continue to the conclusion of the pregnancy.', 'Subjects should be instructed to continue contraception for 180 days after their last dose of study', 'drug.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 87 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '9.5.5.3 Medical History', \"Medical history, including tobacco use history and Graves' disease and treatment history, will be\", 'conducted at Screening. TED must be moderate to severe in intensity (non-sight threatening but', 'appreciable impact on daily life) with an onset of ophthalmic symptoms (as determined by', 'subject records) within 9 months prior to the Baseline Visit for study enrollment.', '9.5.5.4 Vital Signs', 'Vital signs (heart rate, blood pressure, respiratory rate, temperature) will be measured at all clinic', 'visits. Vital signs will be measured pre- and post-infusion on Day 1 and Week 3, and predose on', 'all other infusion days. In addition, if immediate infusion-associated events are noted during the', 'infusion, vital signs will be monitored every 5 minutes until stable and then every 15 minutes for', '2 additional determinations. Also, vital signs will be monitored every 15 minutes from the start', 'of the infusion through 60 minutes after infusion completion for any subsequent infusions after', 'the previous occurrence of immediate or delayed infusion-associated events.', \"Blood pressure and pulse measurements will be obtained with the subject's arm unconstrained by\", 'clothing or other material and while the subject is sitting up. When possible, the same arm will', 'be used for measurements in all study visits.', '9.5.5.5 Physical and Ophthalmic Examinations, Height, and Weight', 'A physical examination, including complete undilated ophthalmic examination, will be', 'performed at Screening, Baseline (Day 1) and thereafter at Weeks 1, 6, 12, 18, and 24 (or PW)', 'during the Treatment Period and at Weeks 48 and 72 (or PW) of the Follow-Up Period.', 'The ophthalmic exam should include best-corrected visual acuity, pupil exam, color vision', 'assessment, Ishihara color plates (or equivalent) or related red desaturation, intraocular pressure', 'and slit lamp exam. If significant abnormalities are noted compared with previous visits,', 'including a loss of 2 lines or more of vision, development of pupil abnormalities including', 'afferent pupillary defect (APD), rise in intraocular pressure, development of corneal infiltrates or', 'other abnormalities not here specified but of concern to the ophthalmologist, further', 'investigations of visual function will be conducted according to the ophthalmologist decision.', 'Subjects who have decreased best-corrected visual acuity due to optic neuropathy (defined by a', 'decrease in vision of 2 lines on the Snellen chart, new visual field defect, or color defect', 'secondary to optic nerve involvement within the last 6 months) at Screening are not eligible for', 'enrollment.', 'New findings reported from on-study ophthalmic examinations will not be reported as AEs if,', 'according to the Investigator, the abnormalities are related to TED and not related to the study', 'drug.', 'Physical exam will include assessment of presence or absence of pretibial myxedema on Day 1,', 'Week 24 (or PW) of the Treatment Period, and Week 72 (or PW) of the Follow-Up Period. If', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 88 of 117']\n\n###\n\n", "completion": "END"}